Cannabinoid Tablet Homogeneity via Colloidal Silicon Dioxide
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type II diabetes only slow the progression of the disease and do not provide a cure, leading to complications such as neuropathy, retinopathy, and cardiovascular disease.
Innovation Solution
Development of Cannabinoid Products containing cannabinoids, specifically formulated into tablets and capsules, which include cannabinoid oil, colloidal silicon dioxide particles, fillers, disintegrants, and lubricants, to provide a homogeneous and stable dosage form for treating diabetic symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If current diabetes treatments are used to slow disease progression, then the progression of type II diabetes is slowed, but they do not provide a cure and lead to complications such as neuropathy
Solution Approach 1:
The patent applies parameter changes by transitioning from conventional diabetes management to cannabinoid-based treatment with specific dosing regimens. The composition includes cannabinoids in controlled amounts (0.1-100mg per day) combined with specific excipients to achieve therapeutic effects that address both disease progression and complications like neuropathy, representing a fundamental change in treatment parameters
2Manufacturing precision
If cannabinoid oil is formulated into tablets or capsules, then consistent dosage delivery is achieved, but the cannabinoids may separate from the composition during compression or encapsulation
Solution Approach 1:
The patent uses colloidal silicon dioxide as an intermediary carrier material that absorbs and stabilizes the cannabinoid oil within the tablet or capsule matrix. This mediator prevents phase separation during manufacturing while ensuring uniform distribution and consistent delivery of cannabinoids throughout the dosage form
Solution Approach 2:
The invention creates a composite material system combining cannabinoid oil with colloidal silicon dioxide, fillers, disintegrants, and lubricants. This composite formulation maintains homogeneity during compression and encapsulation while enabling precise dosage control, resolving the contradiction between manufacturing precision and compositional stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Cannabinoid Products effectively maintain the stability and homogeneity of cannabinoids, ensuring consistent delivery and potentially providing relief for diabetic neuropathy and other related symptoms.
Implementation Method 1
When a Cannabinoid Product described herein is compressed to form a tablet or encapsulated in a shell to form a capsule, the cannabinoids do not separate from the composition
Implementation Method 2
a filler comprising silicified microcrystalline cellulose or mannitol
Implementation Method 3
a lubricant comprising sodium stearyl fumarate
Data Source
AI summary
The present disclosure provides compositions containing Cannabinoid Products and methods of making the same. The disclosure also provides tablets and capsules containing Cannabinoid Products and methods of making the tablets and capsules. The disclosure also provides pharmaceutical products for treating diabetic ailments including diabetic neuropathy.